Related Experiment Video

Updated: Feb 14, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.5K

The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529

Xujun Hu1, Zirui Wang2, Meikai Chen1

  • 1Department of Orthopaedics, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.

Biochemical and Biophysical Research Communications
|February 13, 2018
PubMed

Insights

The mTOR inhibitor RES-529 effectively combats human osteosarcoma (OS) by halting cell growth and proliferation. This dual inhibitor shows potent anti-tumor activity in vitro and in vivo, offering a promising therapeutic strategy for OS.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Over-activation of the mechanistic target of rapamycin (mTOR) pathway is a key driver in human osteosarcoma (OS) development and progression.
  • Targeting the mTOR pathway presents a potential therapeutic strategy for OS treatment.

Purpose of the Study:

  • To investigate the efficacy of RES-529, a novel mTORC1/2 dual inhibitor, against human osteosarcoma cells both in vitro and in vivo.
  • To elucidate the molecular mechanisms underlying RES-529's anti-cancer effects.

Main Methods:

  • RES-529 treatment of established and primary human OS cells, assessing viability, cell cycle, proliferation, and apoptosis.
  • Analysis of mTORC1 and mTORC2 complex assembly and activation.
  • Evaluation of reactive oxygen species (ROS) production and mitochondrial membrane potential.
  • In vivo studies using U2OS xenograft models in SCID mice to assess tumor growth inhibition.

Main Results:

  • RES-529 significantly inhibited OS cell viability, proliferation, and cell cycle progression while inducing apoptosis.
  • RES-529 demonstrated selectivity, being non-cytotoxic to normal osteoblasts.
  • The drug disrupted mTORC1 and mTORC2 complex assembly, blocking pathway activation and leading to ROS production and mitochondrial depolarization.
  • RES-529 exhibited superior potency compared to other Akt-mTOR inhibitors and significantly suppressed tumor growth in vivo.

Conclusions:

  • RES-529 is a potent mTORC1/2 dual inhibitor with significant anti-osteosarcoma activity in vitro and in vivo.
  • RES-529 represents a promising therapeutic agent for human osteosarcoma, warranting further clinical investigation.
Keywords:
Akt and molecularly-targeted therapyOsteosarcomaRES-529mTOR

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.3K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.0K
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH301:11

ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

All ortho–para directors, excluding halogens, are activating groups. These groups donate electrons to the ring, making the ring carbons electron-rich. Consequently, the reactivity of the aromatic ring towards electrophilic substitution increases. For instance, the nitration of anisole is about 10,000 times faster than the nitration of benzene. The electron-donating effect of the methoxy group in anisole activates the ortho and para positions on the ring and stabilizes the corresponding...
7.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H01:13

meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for...
6.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
718